Clinical Trials Logo

Coronary Artery Disease clinical trials

View clinical trials related to Coronary Artery Disease.

Filter by:

NCT ID: NCT00565500 Completed - Osteoarthritis Clinical Trials

Celecoxib, Ibuprofen and the Antiplatelet Effect of Aspirin

Start date: April 2003
Phase: Phase 4
Study type: Interventional

Study design: Single center, placebo-controlled, double blind, parallel groups. To evaluate the potential interaction between aspirin and ibuprofen or celecoxib in patients with osteoarthritis (OA) and documented stable ischemic heart disease, a total of 24 patients chronically treated with aspirin will be randomly assigned to one of the 3 treatment groups: 1) celecoxib 200 mg bid; 2) ibuprofen 600 mg tid; 3) placebo.

NCT ID: NCT00564824 Completed - Coronary Disease Clinical Trials

The Impact of Caffeine on Brachial Endothelial Function in Healthy Subjects and in Patients With Ischemic Heart Disease

Start date: November 2007
Phase: Phase 3
Study type: Interventional

Prior work (Chris, M. et al, Clinical Science 2005; 109, 55-60) has demonstrated that drinking a cup of coffee (80-100 mg of caffeine) an hour before endothelium-dependent FMD (flow-mediated dilatation) of the brachial artery, effects endothelial function in healthy adults subjects. This effect might be attributed to caffeine, given that decaffeinated coffee (<2 mg of caffeine) was not associated with any change in endothelial performance. In the current study we intend to further examine the impact of caffeine on brachial endothelial function among healthy subjects & in patients with proven ischemic heart disease.

NCT ID: NCT00563901 Completed - Hypertension Clinical Trials

Analyzing How Genetics May Affect Response to High Blood Pressure Medications

Start date: September 2000
Phase: N/A
Study type: Observational

High blood pressure is one of the most common health problems in the United States. There are many medications to treat high blood pressure, but there is a large variance in how people respond to these medications. It is believed that genetic variations may contribute to the inconsistent treatment response. This study will use genetic analysis to determine whether particular genes interact with high blood pressure medications to modify the risk of certain cardiovascular diseases.

NCT ID: NCT00562952 Completed - Clinical trials for Coronary Artery Disease

Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients

PONTIAC
Start date: November 2007
Phase: Phase 2/Phase 3
Study type: Interventional

Increased levels of NT-proBNP are known to increase the risk of cardiac events in diabetic patients. The other way around, patients with normal values have an excellent prognosis on short-term. We intend in our study to proof the hypothesis, whether it is possible to decrease NT-proBNP levels by intensified cardiac prevention care We aim those patients, who already have elevated levels, although no history of a cardiac disease. This decrease in NT-proBNP should be translated consequently in a decrease in cardiac events

NCT ID: NCT00562679 Completed - Clinical trials for Coronary Artery Disease

Coronary Artery Disease and Sleep Apnea

Start date: March 1992
Phase: N/A
Study type: Observational

The purpose of this study is to determine the effect of sleep apnea on mortality, stroke and myocardial infarction among 408 patients with coronary artery disease referred for evaluation of coronary intervention who were examined with overnight cardio respiratory monitoring between March 1992 and June 1995.

NCT ID: NCT00561028 Completed - Clinical trials for Coronary Artery Disease

Chlamydia and Mycoplasma in Coronary Artery Disease

Start date: March 2002
Phase: N/A
Study type: Observational

To test the association between anti-Chlamydia serum titers and anti-Mycoplasma antibodies with Acute Coronary Syndromes.

NCT ID: NCT00560209 Completed - Clinical trials for Coronary Artery Disease

Study of ONO-1101 in Patients Scheduled for Coronary Angiography

Start date: November 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of ONO-1101 in patients scheduled for coronary angiography, in a double-blind, randomized, placebo-controlled, parallel group, multi-center study.

NCT ID: NCT00558792 Completed - Clinical trials for Coronary Artery Disease

Coronary MDCTA With Iopamidol Injection 370

Start date: November 2007
Phase: Phase 2
Study type: Interventional

Determine the validity and compare the visualization of arterial segments obtained with 3 doses of iopamidol to determine dose for further investigation in future trials.

NCT ID: NCT00554242 Completed - Clinical trials for Coronary Artery Disease

Effect of Grape Seed Extract Plus Ascorbic Acid on Endothelial Function

Start date: July 2007
Phase: N/A
Study type: Interventional

A pilot study of 15 subjects will be conducted to confirm an acute effect of grape seed extract on endothelial function. We then will perform a a randomized, double blind, placebo controlled crossover study designed to investigate the benefit of grape seed extract/vitamin C treatment on endothelial function. Participants (n=40) will take a food supplement containing 450 mg of grape seed extract and 1500 mg of vitamin C or matching placebo for four weeks and then cross over to the alternative treatment (active supplement or placebo) for four weeks. We will examine endothelial function before and after each of the two treatment periods. The study will provide information about the vascular effects of these compounds.

NCT ID: NCT00554203 Completed - Clinical trials for Coronary Artery Disease

Sulfasalazine and Endothelial Function

Start date: July 2003
Phase: N/A
Study type: Interventional

Experimental studies suggest that systemic inflammation leads to endothelial dysfunction and atherosclerosis. This study will examine the effects of the anti-inflammatory drug sulfasalazine on endothelial function in patients with coronary artery disease. Subjects will be treated with sulfasalazine or to placebo for six weeks. After a two-week rest period, subjects will cross over to the alternative treatment. Endothelium-dependent flow-mediated dilation of the brachial artery will be studied before and after each drug. We hypothesize that anti-inflammatory therapy will reverse endothelial dysfunction in patients with coronary artery disease.